Dataset Information


T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.

ABSTRACT: T-cell lymphoma is a neoplasm that expresses markers of T-cell or natural killer cell (NK)-origin but not those of B-cell origin. Although B-cell lymphoma with abundant expression of T-cell markers exist, the opposite is very rare. Therefore, little is known about this subtype of lymphoma, including its treatment and prognosis.A 65-year-old man was diagnosed with T-cell lymphoma with abundant CD20 expression. He was refractory to cyclophosphamide + epirubicin + vincristine + prednisone + etoposide (CHOPE), ifosfamide + cisplatin + etoposide + dexamethasone (DICE), and hyper-cyclophosphamide + vincristine + epirubicin + dexamethasone (CVAD) chemotherapy. The patient was also treated with prednisone + thalidomide + chidamide, which was also not effective. Upon admission to our department, he was administered a rituximab + gemcitabine + oxiplatin + L-asparaginase (R-pGEMOX) regimen and achieved partial remission.CD20-positive T-cell lymphoma is a very rare type of lymphoma that is refractory to CHOP-like regimens alone. Rituximab may be effective in patients showing abundant CD20 expression, and an R-pGEMOX regimen will likely be effective, even in refractory/recurrent patients.


PROVIDER: S-EPMC5895354 | BioStudies | 2018-01-01


REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3724189 | BioStudies
2016-01-01 | S-EPMC5078781 | BioStudies
2009-01-01 | S-EPMC2738717 | BioStudies
2010-01-01 | S-EPMC2858478 | BioStudies
2019-01-01 | S-EPMC6700039 | BioStudies
2015-01-01 | S-EPMC4542576 | BioStudies
1000-01-01 | S-EPMC3755934 | BioStudies
2014-01-01 | S-EPMC4191682 | BioStudies
2016-01-01 | S-EPMC5078030 | BioStudies
2018-01-01 | S-EPMC6278976 | BioStudies